Tag: clinical outsourcing

Documenting Performance Management & SLAs for Audits, Health Authority Queries and Due Diligence Documenting Performance Management & SLAs for Audits, Health Authority Queries and Due Diligence Understanding the Importance of Performance Management in Clinical Trials In the realm of clinical trials, especially in regulatory environments governed by agencies like the FDA, EMA, and MHRA, the…

Read More “Documenting Performance Management & SLAs for Audits, Health Authority Queries and Due Diligence” »

Digital Tools and Automation That Transform Performance Management & SLAs in Clinical Development Digital Tools and Automation That Transform Performance Management & SLAs in Clinical Development In today’s rapidly evolving clinical research landscape, the integration of digital tools and automation plays a crucial role in enhancing the performance of clinical trials. The adoption of clinical…

Read More “Digital Tools and Automation That Transform Performance Management & SLAs in Clinical Development” »

Case Studies: Performance Management & SLAs That Rescued High-Risk Studies and Vendors Case Studies: Performance Management & SLAs That Rescued High-Risk Studies and Vendors In the highly regulated environment of clinical trials, maintaining performance management and Service Level Agreements (SLAs) is crucial, particularly in high-risk studies. This comprehensive tutorial guides clinical operations, regulatory affairs, and…

Read More “Case Studies: Performance Management & SLAs That Rescued High-Risk Studies and Vendors” »

Integrating Performance Management & SLAs With QMS, Risk Registers and Governance Committees Performance management and Service Level Agreements (SLAs) are vital components of clinical trial operations, particularly in the context of CDMS clinical trials. The successful execution of clinical trials requires robust mechanisms that ensure compliance with regulatory standards and operational excellence. This tutorial provides…

Read More “Integrating Performance Management & SLAs With QMS, Risk Registers and Governance Committees” »

Future-Proofing Performance Management & SLAs for AI, Real-World Data and Platform Trials Future-Proofing Performance Management & SLAs for AI, Real-World Data and Platform Trials In the rapidly evolving landscape of clinical trials, particularly in areas such as clinical trials for small cell lung cancer, there is an increasing emphasis on the integration of advanced technologies,…

Read More “Future-Proofing Performance Management & SLAs for AI, Real-World Data and Platform Trials” »

Aligning Performance Management & SLAs With ICH E6(R3), GCP and Quality-by-Design Principles Aligning Performance Management & SLAs With ICH E6(R3), GCP and Quality-by-Design Principles Introduction: Importance of Performance Management in Clinical Trials In the rapidly evolving landscape of clinical research, aligning performance management frameworks with regulatory standards such as ICH E6(R3) and Good Clinical Practice…

Read More “Aligning Performance Management & SLAs With ICH E6(R3), GCP and Quality-by-Design Principles” »

Performance Management & SLAs Checklists for Clinical Operations and Vendor Governance Teams Effective performance management and stringent adherence to Service Level Agreements (SLAs) are paramount in the realm of clinical trials. This is particularly vital in platform clinical trial settings, where multiple stakeholders, including Contract Research Organizations (CROs) and site management teams, are involved in…

Read More “Performance Management & SLAs Checklists for Clinical Operations and Vendor Governance Teams” »

Common Pitfalls in Performance Management & SLAs—and How to Avoid Regulatory Findings Common Pitfalls in Performance Management & SLAs—and How to Avoid Regulatory Findings In the context of clinical trials, performance management and service level agreements (SLAs) are pivotal in ensuring compliance with regulatory standards while promoting operational effectiveness. Effective vendor oversight and engagement with…

Read More “Common Pitfalls in Performance Management & SLAs—and How to Avoid Regulatory Findings” »